Provided by Tiger Trade Technology Pte. Ltd.

LUCID DIAGNOSTICS INC.

0.6235
+0.02353.92%
Post-market: 0.64000.0165+2.65%19:30 EDT
Volume:1.71M
Turnover:1.08M
Market Cap:126.72M
PE:-1.35
High:0.6530
Open:0.5910
Low:0.5875
Close:0.6000
52wk High:1.63
52wk Low:0.5000
Shares:203.24M
Float Shares:152.47M
Volume Ratio:0.61
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4616
EPS(LYR):-0.6922
ROE:-556.27%
ROA:-81.62%
PB:11.60
PE(LYR):-0.90

Loading ...

Needham sees no reason for Lucid Diagnostics selloff today

TIPRANKS
·
Oct 02

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

TIPRANKS
·
Sep 22

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

TIPRANKS
·
Aug 14

Press Release: PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 14

Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision

TIPRANKS
·
Aug 13

PAVmed Subsidiary Lucid Diagnostics Posts 2Q Revenue of USD 1.5 Million

Reuters
·
Aug 13

Press Release: Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Lucid Diagnostics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Lucid Diagnostics Inc: Qtrly REV $1.5 Mln, EPS $-0.08 - SEC Filing

THOMSON REUTERS
·
Aug 13

Lucid Diagnostics Q2 FY26 Revenue Rises 25% to USD 1.5 Million

Reuters
·
Aug 13

Lucid Diagnostics Inc Expected to Post a Loss of 7 Cents a Share - Earnings Preview

Reuters
·
Aug 11

PAVmed Unit Lucid Diagnostics Wins Concert Commercial Coverage Policy for EsoGuard Test

Reuters
·
Aug 05

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for Its Esoguard® Esophageal DNA Test

THOMSON REUTERS
·
Aug 05

Lucid Diagnostics to Present at Needham, Canaccord Investor Conferences

Reuters
·
Aug 04

Lucid Diagnostics Management Participates in Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Aug 04

Lucid Diagnostics Schedules Business Update Call to Discuss Q2 2026 Results

Reuters
·
Jul 30

Lucid Diagnostics Shareholders Approve Stock Authorization Increase

TIPRANKS
·
Jun 25

Lucid Diagnostics Shareholders Approve Charter Amendment Raising Authorized Common Shares to 400 Million

Reuters
·
Jun 25

Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00

Reuters
·
May 22

PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million

Reuters
·
May 15